$IBRX News

ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears

ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC

ImmunityBio Completes Database Lock For Cohort A Of QUILT-2.005, Randomized, Controlled, Registrational Trial Evaluating ANKTIVA In Combination With BCG Versus BCG Alone In Patients With BCG-Naïve NMIBC

ANKTIVA Label Expansion Could Change The Case For ImmunityBio Stock

ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment

ImmunityBio: Not Executing At The Level That The Market Is Pricing In

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

ImmunityBio Announces Data From Its Phase 2/3 QUILT-3.032 Trial Of ANKTIVA In Combination With Bacillus Calmette-Guerin Demonstrates 71% Complete Response Rate In Participants With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ

ImmunityBio: Jury May Still Be Out On Anktiva Despite Latest NMIBC Win

Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14

ImmunityBio Stock Climbs Thursday: What's Going On?

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline

Why Is ImmunityBio Stock Gaining Wednesday?

FDA Approves ImmunityBio's Anktiva To Treat Adults With Bacillus Calmette-Guerin Unresponsive Non-Muscle Invasive Bladder Cancer

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

ImmunityBio (IBRX) Could Be 33% Undervalued Following Its Ottawa Symposium Update